Intervention with cash lottery prizes cuts HIV infection by 39% in young women in Lesotho

HIV testing in Vancouver. Image provided by BC Centre for Excellence in HIV/AIDS (
Roger Pebody
Published: 04 July 2013

An HIV prevention intervention in which young people who had tested negative for sexually transmitted infections were given lottery tickets and had the possibility of winning a cash prize reduced the number of HIV infections by 39% in young women, researchers reported to the 7th International AIDS Society conference (IAS 2013) this week. However, the intervention did not have any impact on young men in this trial in Lesotho.

Evaluations of HIV prevention interventions which measure biological outcomes (such as new infections) rather than improvements in knowledge or attitudes, are few and far between. Behavioural interventions which demonstrate an efficacy of this magnitude are even rarer.

The conference also heard that financial incentives have improved HIV testing rates in drug users in a Canadian study.

In recent years, interest in the possibility of influencing health behaviours through conditional cash transfers and other financial incentives has been growing. Aidsmap has reported on discussions of the ethics, feasibility and effectiveness of these approaches at international conferences in 2010, 2011 and 2012.

Lesotho lottery

Lesotho has an exceptionally high prevalence of HIV, especially amongst young people. The study tested the hypothesis that a system of rapid feedback and positive reinforcement, using a lottery scheme as an incentive to reduce risky sexual behaviour, could be used to promote safer sex and reduce HIV incidence in young people.

Study participants were 3426 men and women, aged between 18 and 32, living in one of 29 villages in Lesotho. Participants were randomised to join one of three arms – high-value lottery, low-value lottery, or the control arm (no intervention). While the study was randomised, it was unblinded – people knew whether they were taking part in a lottery or not.

All participants received testing for sexually transmitted infections (STIs), STI treatment if necessary, and counselling every four months for two years. All participants were tested for HIV at baseline and after 16, 20 and 24 months.

If a participant in one of the intervention arms had tested negative for syphilis and Trichomonas vaginalis he or she received a lottery ticket. If the participant was in the high-value arm of the study, it was worth 1000 malotis or South African Rand, approximately USD 100). If he or she was in the low-value arm, the lottery ticket was worth 500 malotis or South African rand, USD 50).

A lottery was organised in each village, every four months. There were two male winners and two female winners from each village. With around 50 to 70 entrants per village, individuals had a relatively good chance of winning, but only those who had remained STI-free could enter.

The evaluation assessed the effectiveness of the programme in reducing new HIV infections after two years.

In young men, the programme had no impact. Compared to men in the control arm, those taking part in the lottery were just as likely to acquire HIV (adjusted odds ratio 1.25, 95% confidence interval 0.67-2.35).

But the intervention was effective for young women, reducing infection rates by 33% if we consider both lottery arms together (adjusted odds ratio 0.67, 95% CI 0.52-0.86).

And the intervention was most effective for those whose lottery ticket could be worth 1000 malotis ($100). In the high-value lottery arm, new HIV infections were reduced by 39% (adjusted odds ratio 0.61, 95% CI 0.45-0.84).

Amongst young women not receiving the intervention, 6.6% had acquired HIV by 16 months, 11.6% by 20 months, and 14.6% by 24 months.

In contrast, in those eligible for the higher value ticket, incidence was 4.7%, 7.2% and 10.6% respectively.

Cash incentives for HIV testing

The conference also heard results of an intervention in Vancouver, Canada to improve engagement of drug users in HIV testing and post-test follow-up. It is generally more feasible to use financial incentives to facilitate a discrete, time-limited health behaviour such as testing or vaccination, in contrast to sustained sexual behaviour change, as seen in Lesotho.

Eligible participants were drug users (including heroin, crystal methamphetamine etc., but not marijuana) who were either untested or had previously been diagnosed but had dropped out of care. Three hundred and one were randomised to either be offered standard counselling and testing, or $10 following blood sampling and a further $15 if they actually came back for their results.

Far more individuals were tested (100%) and came back for results (83%) in the intervention arm than in the control arm (32 and 11% respectively). The prevalence of HIV and newly diagnosed hepatitis C was high in those taking part (10 and 17% respectively).

However, the study results do raise some questions. The theory of financial incentives is that they should help people to achieve outcomes that they desire but might struggle to achieve otherwise. With only a third of participants in the control arm choosing to test (never mind get their results), it appears that some participants were only in it for the money. Moreover, the benefit of HIV diagnosis lies in receiving HIV treatment (and facilitating behaviour change), so future studies should assess engagement with medical care, rather than just getting test results.


Björkman-Nyqvist M et al. Evaluating the impact of short term financial incentives on HIV and STI incidence among youth in Lesotho: a randomized trial. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, abstract TUPDC0106, 2013. View this abstract on the conference website.

View details of the conference session, Tomorrow Starts Today: HIV and Adolescents, in which this abstract was presented, including some presentation slides, on the conference website.

Hull M et al. Use of modest financial incentives to improve engagement of drug users in HIV testing and follow-up: results of a randomized controlled trial. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, abstract TUAC0203, 2013. View this abstract on the conference website.

View details of the conference session, Prevention among People Who Inject Drugs: What Works, in which this abstract was presented, including some presentation slides and webcasting, on the conference website.

Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email

NAM’s IAS 2013 bulletins have been made possible thanks to support from Bristol-Myers Squibb. NAM's wider conference news reporting services have been supported by Boehringer Ingelheim and Janssen.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.